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Background
The introduction of HAART has significantly pro-
longed the life span of HIV-infected patients. However,
the error-prone nature of HIV-1 reverse transcriptase
(HIV-1 RT) results in the emergence of drug-resistant
viruses and threatens the effectiveness of HAART.
HIV-1 RT is a primary target of two classes of drugs:
nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors
(NNRTIs). Recent phase III clinical trials have shown
that two HIV-1 RT mutations, E138K and M184I, were
the most frequent mutations found in patients that
experienced virological failure during therapy that
included rilpivirine (RPV), emtricitabine (FTC), and
tenofovir (TDF).
Methods
To investigate the mechanistic basis for resistance
caused by the E138K and M184I mutations we used
transient kinetics to characterize the enzymatic proper-
ties and drug susceptibility of RTs with these mutations
and determined the biochemical mechanism of resis-
tance to RPV. Specifically, we compared wild-type (WT)
RT to RTs mutated in one or both of the enzymatic
subunits: p66M184I/p51M184I, p66E138K/p51E138K,
p66E138K/p51M184I, p66E138K/p51WT, p66WT/
p51138K.
Results
Our results show that M184I reduces the catalytic effi-
ciency of RT by more than two-fold (p66M184I/
p51M184Ihas more than 2-fold reduced kpol/Kd.dNTP
with respect to WT). This defect is compensated by
mutation E138K either in both subunits or only in p51
subunit (p66WT/p51138K).
Conclusion
None of the mutations affected the template-primer
binding affinity of RT. As expected, M184I does not
reduce the susceptibility to RPV. Instead, RPV resistance
is achieved by reduction in the binding affinity of the
drug to RT because of the E138K mutation in the p51
subunit.
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